Development of peptide antagonists that target estrogen receptor-cofactor interactions

Journal of Steroid Biochemistry and Molecular Biology

Volumn 74, Issue 5, 2000, Pages 327-335

  McDonnell, Donald P ^a   Chang, Ching Yi ^a   Norris, John D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Estrogen; Peptide antagonists; Receptor cofactor interaction; Transcriptional activity

Indexed keywords

ANTIESTROGEN; CELL NUCLEUS RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PEPTIDE DERIVATIVE; RECEPTOR SUBTYPE; TAMOXIFEN; TRANSCRIPTION FACTOR;

AMINO ACID SEQUENCE; BINDING AFFINITY; BREAST CANCER; CANCER THERAPY; COMPETITIVE INHIBITION; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; DRUG BINDING SITE; DRUG RECEPTOR BINDING; HORMONE RECEPTOR INTERACTION; HUMAN; TRANSCRIPTION REGULATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; RECEPTORS, ESTROGEN; SUBSTRATE SPECIFICITY; TAMOXIFEN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 0034735872     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(00)00109-6     Document Type: Conference Paper

References (47)

1. Female sex steroids: Receptors and function
2. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
3. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
4. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity
5. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
6. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
7. Nuclear receptor coregulators: Cellular and molecular biology
8. Steroid receptor coactivator-1 is a histone acetyltransferase
9. Enhancement of estrogen receptor transcriptionl activity by the coactivator GRIP-I highlights the role of activation function 2 in determining estrogen receptor pharmacology
10. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
11. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene
12. A transcriptional co-repressor that interacts with nuclear hormone receptors
13. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
14. Diverse signaling pathways modulate nuclear receptor recruitment of NCoR and SMRT complexes
15. Anti-estrogens come of age: A pioneer looks back
16. How is tamoxifen's action subverted?
17. Toremifene and tamoxifen in advanced breast cancer - A double-blind cross over trial
18. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
19. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
20. Overviews of adjuvant tamoxifen therapy
21. Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistent breast cancer
22. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
23. Tamoxifen for adjuvant therapy and for the treatment of advanced disease in premenopausal breast cancer patients
24. Comparative analyses of the mechanistic differences among antiestrogens
25. Tissue selective estrogen receptor modulators: A concept reduced to practice
26. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
27. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
28. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
29. A canonical structure for the ligand-binding domain of nuclear receptors
30. Identification of novel human WW domain-containing proteins by cloning of ligand targets
31. Cloning of ligand targets: Systematic isolation of SH3 domain-containing proteins
32. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatonial peptide libraries: Discovery of peptide antagonists of estrogen receptors α and β
33. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation
34. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation
35. 8,9 dehydroestrone sulfate in postmenopausal women
36. Molecular basis of agonism and antagonism in the oestrogen receptor
37. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ
38. 2, activate estrogen receptors (ER) and induce galanin (GAL) gene expression in immortalized LHRH neurons
39. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell and promoter-specific action of these hormones
40. Peptide antagonists of the human estrogen receptor
41. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
42. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
43. Design of peptidornimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-β receptor and possess cellular activity
44. From peptides to drugs via phage display
45. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 Å
46. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor
47. Small peptides as potent mimetics of the protein hormone erythropoietin